Publications by authors named "Qian-Zhan Yang"
Bile acids (BAs), the primary components of bile, play significant roles in sugar, lipid, and cholesterol metabolism. Normal BA metabolism maintains a dynamic equilibrium by regulating gut microbiota to effectively protect the liver and intestines, thereby sustaining overall health. Conversely, abnormal BA metabolism can cause intestinal tissue and liver damage, disruption of enterohepatic circulation homeostasis, dysbiosis of gut microbiota, and gastrointestinal and hepatic diseases.
View Article and Find Full Text PDFArticle Synopsis
- - A20 is a molecule in nucleus pulposus (NP) cells that has anti-inflammatory effects primarily through suppressing the NF-κB pathway, but it can also protect cells from death through other means.
- - The study used an in vitro model to observe how A20 influences cell death (apoptosis and pyroptosis) and mitophagy in NP cells when induced by lipopolysaccharide (LPS).
- - Results indicated that LPS treatment led to increased apoptosis and pyroptosis over time, while A20 helped reduce these cell death processes and inflammatory cytokine production, promoted mitophagy, and supported mitochondrial health despite the presence of LPS.
Ruxolitinib attenuates secondary injury after traumatic spinal cord injury.
Neural Regen Res
September 2022
Article Synopsis
- Excessive inflammation after spinal cord injury activates microglia, contributing to long-term neurological problems, and the exact mechanisms behind this activation are not well understood.
- Ruxolitinib (RUX), a drug that inhibits certain inflammatory pathways, was tested on microglia and in a mouse model of spinal cord injury, showing that it reduced pro-inflammatory markers and microglial proliferation.
- The study suggests that RUX limits neuroinflammation by blocking the interferon-γ/JAK/STAT signaling pathway, leading to improved neuromotor function and less damage to nerve fibers post-injury.
Article Synopsis
- Excess activation of inflammatory microglia worsens spinal cord injury (SCI), and inhibiting the protein Arhgef3 can reduce this inflammation.
- In laboratory tests and animal models, increased Arhgef3 levels were linked to heightened microglial activity and inflammatory responses.
- Reducing Arhgef3 not only lowered inflammation and reactive oxygen species production after injury but also led to improved recovery and reduced secondary damage in mice, suggesting it may be a potential target for treating SCI.